# Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution

> **NCT03967665** · PHASE3 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 130 (actual)

## Conditions studied

- Stem Cell Transplant Complications

## Interventions

- **DRUG:** N-acetyl-L-cysteine

## Key facts

- **NCT ID:** NCT03967665
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2021-09-05
- **Final completion:** 2024-10-01
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2021-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03967665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03967665, "Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03967665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*